Substipharm SAS and Athena Pharmaceutiques, are proud to announce the acquisition of a majority stake in Vectans Pharma SAS, a pharmaceutical company recognized for its proprietary Lauriad® muco-adhesive drug delivery technology.

This alliance leverages the strengths of Substipharm and Athena to fast-track Vectans Pharma’s innovation pipeline and broaden its global footprint. It creates a robust platform to grow the Lauriad® franchise, enter new markets, and enhance value through streamlined operations.